Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 6,080 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

NCT01241344
View directory record Official record
Conditions
Adenovirus Disease
Interventions
Brincidofovir, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
3 Months to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 30, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT07673744
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Ublituximab, Placebo
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Maitland, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Proxalutamide (GT0918) in Hospitalized COVID-19 Subjects

NCT05009732
View directory record Official record
Conditions
Covid19
Interventions
GT0918, Standard of care, Matching placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Hialeah, Florida • Lansing, Michigan • Hannibal, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 2 Interventional

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

NCT02475447
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate EDP 938 Regimens in Children With RSV

NCT04816721
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
28 Days to 36 Months
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 30, 2026, 2:26 PM EDT
Terminated Phase 3 Interventional

Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

NCT04968184
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Placebo, KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 30, 2026, 2:26 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Metabolomic Study for Localized Prostate Cancer

NCT01968538
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 30, 2026, 2:26 PM EDT
Not yet recruiting Not applicable Interventional

Accelerated and Extended-iTBS Targeting Inhibitory Control in Veterans With ADHD

NCT07442058
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Intermittent Theta-Burst Stimulation, Sham Stimulation
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection

NCT00822692
View directory record Official record
Conditions
Abscess, Methicillin-Resistant Staphylococcus Aureus Infection
Interventions
Trim/ Sulfa DS, placebo
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 1 Interventional

A Study With GLPG1972 in Osteoarthritis Subjects

NCT03311009
View directory record Official record
Conditions
Osteoarthritis
Interventions
GLPG1972 cohort 1, GLPG1972 cohort 2, GLPG1972 cohort 3, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
50 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

NCT03904693
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Interventions
FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg, Placebo FDC, Placebo macitentan, Placebo tadalafil
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
26
States / cities
Fullerton, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

NCT01399684
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Not applicable Interventional Results available

Targeting of UnControlled Hypertension in Emergency Department

NCT03749499
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions
HTN Educational Video, Visual Echocardiogram Image Clips, Mobile Health and Remote BP monitoring, Post-Acute Care HTN Transition consultation (PACHT-c)
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo and Positive Controlled Study to Evaluate the Cardiovascular Effect of Tetrodotoxin in Healthy Adult Subjects

NCT04083833
View directory record Official record
Conditions
TQT Study
Interventions
Tetrodotoxin, Placebos
Drug
Lead sponsor
Wex Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 3 Interventional

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

NCT05643534
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
39
States / cities
Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alcohol and Neural Cardiovascular Control in Binge Drinkers

NCT03567434
View directory record Official record
Conditions
Binge Drinking
Interventions
Alcohol vs. Placebo
Other
Lead sponsor
Baylor University
Other
Eligibility
21 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional Results available

Efficacy and Safety of Topiramate in the Treatment of Sleep-Related Eating Disorder

NCT00606411
View directory record Official record
Conditions
Sleep-Related Eating Disorder
Interventions
Topiramate or Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

NCT02784106
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Billerica, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 30, 2026, 2:26 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

NCT07762001
View directory record Official record
Conditions
Maximum Tolerated Dose, Dose Escalation
Interventions
AD-NP1, Placebo
Drug
Lead sponsor
Arjun Deb, MD
Other
Eligibility
21 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)

NCT04008004
View directory record Official record
Conditions
Chronic HBV Infection
Interventions
EDP-514, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
11
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Overlapping Neural Circuits in Pediatric OCD

NCT02421315
View directory record Official record
Conditions
Obsessive Compulsive Disorder
Interventions
CBT treatment for OCD based on Exposure & Response Prevention (EX/RP) and when indicated medication treatment
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
5 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 30, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes

NCT02749214
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Blood Sample Collection, Breath Sample Collection
Other
Lead sponsor
Emory University
Other
Eligibility
25 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 30, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

NCT01894516
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
21
States / cities
Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 30, 2026, 2:26 PM EDT